File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Favorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kong
Title | Favorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kong |
---|---|
Authors | |
Keywords | Medical sciences Oncology medical sciences Pediatrics |
Issue Date | 2013 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/ |
Citation | The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 n. S3, p. 78, abstract no. P0102 How to Cite? |
Abstract | PURPOSE/OBJECTIVE: We aimed to review and compare the outcomes of children with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplant (HSCT) from different types of donors. MATERIALS AND METHODS: We performed a retrospective review of the patient and transplant characteristics and transplant outcomes of children with AML who underwent allogeneic HSCT in our unit. RESULTS: We performed allogeneic HSCT for 42 children (26 males and 16 females) with AML in 1994-2012. The median age at HSCT was 9.2 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission, 19 in second remission, 1 in third remission, and 6 with non-remission. Donors were matched sibling (MS) (n ? 17), 1-antigen mismatched parent (MP) (n ? 2), matched unrelated donor (MUD) (n ? 11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (n ? 12). Five-year overall survival (OS) and relapse-free survival (RFS) were better in patients who received UCB compared to MS, MUD, or MP (OS: 76.2% vs. 32.4% vs. 18.2% vs. 0%; RFS: 71.4% vs. 32.7% vs. 18.2% vs. 0%). The differences in OS and RFS among different types of donors were statistically significant after adjusting for age and remission status (p ? 0.007 for OS and p ? 0.037 for RFS). Transplant-related mortalities in UCB, MS, MUD, and MP were 0%, 17.6%, 72.7% and 50% respectively. CONCLUSIONS: Outcomes were favorable for pediatric AML patients who received unrelated cord blood transplant compared to other types of donors in our unit. |
Description | This journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013 Poster Session - Myeloid leukemias - abstarct no. P-0102 |
Persistent Identifier | http://hdl.handle.net/10722/193637 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.992 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheuk, DKL | en_US |
dc.contributor.author | Chiang, A | en_US |
dc.contributor.author | Ha, SY | en_US |
dc.contributor.author | Chan, G | en_US |
dc.date.accessioned | 2014-01-20T05:12:15Z | - |
dc.date.available | 2014-01-20T05:12:15Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 n. S3, p. 78, abstract no. P0102 | en_US |
dc.identifier.issn | 1545-5009 | - |
dc.identifier.uri | http://hdl.handle.net/10722/193637 | - |
dc.description | This journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013 | - |
dc.description | Poster Session - Myeloid leukemias - abstarct no. P-0102 | - |
dc.description.abstract | PURPOSE/OBJECTIVE: We aimed to review and compare the outcomes of children with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplant (HSCT) from different types of donors. MATERIALS AND METHODS: We performed a retrospective review of the patient and transplant characteristics and transplant outcomes of children with AML who underwent allogeneic HSCT in our unit. RESULTS: We performed allogeneic HSCT for 42 children (26 males and 16 females) with AML in 1994-2012. The median age at HSCT was 9.2 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission, 19 in second remission, 1 in third remission, and 6 with non-remission. Donors were matched sibling (MS) (n ? 17), 1-antigen mismatched parent (MP) (n ? 2), matched unrelated donor (MUD) (n ? 11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (n ? 12). Five-year overall survival (OS) and relapse-free survival (RFS) were better in patients who received UCB compared to MS, MUD, or MP (OS: 76.2% vs. 32.4% vs. 18.2% vs. 0%; RFS: 71.4% vs. 32.7% vs. 18.2% vs. 0%). The differences in OS and RFS among different types of donors were statistically significant after adjusting for age and remission status (p ? 0.007 for OS and p ? 0.037 for RFS). Transplant-related mortalities in UCB, MS, MUD, and MP were 0%, 17.6%, 72.7% and 50% respectively. CONCLUSIONS: Outcomes were favorable for pediatric AML patients who received unrelated cord blood transplant compared to other types of donors in our unit. | - |
dc.language | eng | en_US |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/ | - |
dc.relation.ispartof | Pediatric Blood & Cancer | en_US |
dc.rights | Pediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc. | - |
dc.subject | Medical sciences | - |
dc.subject | Oncology medical sciences | - |
dc.subject | Pediatrics | - |
dc.title | Favorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kong | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Cheuk, DKL: klcheuk@hkucc.hku.hk | en_US |
dc.identifier.email | Chiang, A: chiangak@hku.hk | en_US |
dc.identifier.email | Ha, SY: syha@hku.hk | en_US |
dc.identifier.email | Chan, G: gcfchan@hku.hk | en_US |
dc.identifier.authority | Chiang, A=rp00403 | en_US |
dc.identifier.authority | Chan, G=rp00431 | en_US |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/pbc.24719 | - |
dc.identifier.hkuros | 227215 | en_US |
dc.identifier.volume | 60 | - |
dc.identifier.issue | suppl. 3 | - |
dc.identifier.spage | 78, abstract no. P0102 | - |
dc.identifier.epage | 78, abstract no. P0102 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1545-5009 | - |